全文获取类型
收费全文 | 106301篇 |
免费 | 7656篇 |
国内免费 | 2687篇 |
专业分类
耳鼻咽喉 | 888篇 |
儿科学 | 1920篇 |
妇产科学 | 2294篇 |
基础医学 | 8846篇 |
口腔科学 | 1959篇 |
临床医学 | 10327篇 |
内科学 | 13336篇 |
皮肤病学 | 840篇 |
神经病学 | 5100篇 |
特种医学 | 3076篇 |
外国民族医学 | 24篇 |
外科学 | 11494篇 |
综合类 | 18072篇 |
现状与发展 | 3篇 |
一般理论 | 4篇 |
预防医学 | 11896篇 |
眼科学 | 1391篇 |
药学 | 9530篇 |
208篇 | |
中国医学 | 9639篇 |
肿瘤学 | 5797篇 |
出版年
2024年 | 277篇 |
2023年 | 1674篇 |
2022年 | 3051篇 |
2021年 | 4468篇 |
2020年 | 4105篇 |
2019年 | 4000篇 |
2018年 | 3671篇 |
2017年 | 3545篇 |
2016年 | 3549篇 |
2015年 | 3261篇 |
2014年 | 6944篇 |
2013年 | 6598篇 |
2012年 | 6196篇 |
2011年 | 7241篇 |
2010年 | 6160篇 |
2009年 | 4990篇 |
2008年 | 4766篇 |
2007年 | 5058篇 |
2006年 | 4441篇 |
2005年 | 3854篇 |
2004年 | 3153篇 |
2003年 | 2846篇 |
2002年 | 2225篇 |
2001年 | 1965篇 |
2000年 | 1620篇 |
1999年 | 1536篇 |
1998年 | 1215篇 |
1997年 | 1201篇 |
1996年 | 1056篇 |
1995年 | 1016篇 |
1994年 | 941篇 |
1993年 | 734篇 |
1992年 | 733篇 |
1991年 | 659篇 |
1990年 | 562篇 |
1989年 | 546篇 |
1988年 | 514篇 |
1987年 | 413篇 |
1986年 | 401篇 |
1985年 | 677篇 |
1984年 | 621篇 |
1983年 | 471篇 |
1982年 | 544篇 |
1981年 | 517篇 |
1980年 | 483篇 |
1979年 | 434篇 |
1978年 | 368篇 |
1977年 | 331篇 |
1976年 | 267篇 |
1975年 | 199篇 |
排序方式: 共有10000条查询结果,搜索用时 500 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
目的 临床观察白花蛇舌草干预湿热瘀滞型肠内多发息肉患者内镜治疗术后复发情况。方法 采用前瞻性的随机空白对照试验设计,选取2019年9月1日—2020年12月31日上海中医药大学附属普陀医院消化科收治的门诊及住院结直肠多发息肉患者132例作为研究对象。采用随机方法分为对照组和试验组,每组66例。对照组行内镜治疗术给予常规治疗后无药物干预,试验组在对照基础上给予白花蛇舌草汤剂(每日取白花蛇舌草15 g、大枣3枚,煎取400 mL汤剂,分2次饭后温服)治疗,连续干预1年。观察并比较两组术前与术后1年肠道内息肉的复发率、息肉数目、息肉最大直径、中医证候评分及肝肾功能及血常规的差异。结果 干预1年后,试验组复发9例(14.75%),对照组复发21例(33.33%),两组息肉复发率比较,差异有统计学意义(P<0.05)。试验组腺瘤、伴重度异型增生、体质量指数(BMI)≥24 kg·m-2患者治疗后息肉复发率均较对照组同类型降低,差异显著(P<0.05);术后1年试验组息肉最大直径及息肉数目均较对照组显著减小,差异显著(P<0.05);术后1年试验组中医证候各项评分均显著低于对照组(P<0.05);术后1年,两组中医证候疗效比较,差异具有统计学意义(P<0.05),且术前、术后1年两组患者肝肾功能、凝血功能等安全性指标无显著差异。结论 应用白花蛇舌草干预结直肠息肉术后患者,1年后明显降低肠内息肉的复发率,尤以腺瘤性息肉、重度异型增生、BMI超重患者更显著,不仅改善临床症状,还能有效预防结直肠息肉的复发,改善患者的预后。 相似文献
4.
5.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
8.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):94-103.e24
ObjectiveNew-onset postoperative atrial fibrillation (POAF) after cardiac surgery is common, with rates up to 60%. POAF has been associated with early and late stroke, but its association with other cardiovascular outcomes is less known. The objective was to perform a meta-analysis of the studies reporting the association of POAF with perioperative and long-term outcomes in patients with cardiac surgery.MethodsWe performed a systematic review and a meta-analysis of studies that presented outcomes for cardiac surgery on the basis of the presence or absence of POAF. MEDLINE, EMBASE, and the Cochrane Library were assessed; 57 studies (246,340 patients) were selected. Perioperative mortality was the primary outcome. Inverse variance method and random model were performed. Leave-one-out analysis, subgroup analyses, and metaregression were conducted.ResultsPOAF was associated with perioperative mortality (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.58-2.33), perioperative stroke (OR, 2.17; 95% CI, 1.90-2.49), perioperative myocardial infarction (OR, 1.28; 95% CI, 1.06-1.54), perioperative acute renal failure (OR, 2.74; 95% CI, 2.42-3.11), hospital (standardized mean difference, 0.80; 95% CI, 0.53-1.07) and intensive care unit stay (standardized mean difference, 0.55; 95% CI, 0.24-0.86), long-term mortality (incidence rate ratio [IRR], 1.54; 95% CI, 1.40-1.69), long-term stroke (IRR, 1.33; 95% CI, 1.21-1.46), and longstanding persistent atrial fibrillation (IRR, 4.73; 95% CI, 3.36-6.66).ConclusionsThe results suggest that POAF after cardiac surgery is associated with an increased occurrence of most short- and long-term cardiovascular adverse events. However, the causality of this association remains to be established. 相似文献
9.
10.